^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    SDHB (Succinate Dehydrogenase Complex Iron Sulfur Subunit B)

    i
    Other names: SDHB, Succinate Dehydrogenase Complex Iron Sulfur Subunit B, Iron-Sulfur Subunit Of Complex II, Succinate Dehydrogenase [Ubiquinone] Iron-Sulfur Subunit, Mitochondrial, Succinate Dehydrogenase Complex, Subunit B, Iron Sulfur (Ip), SDH1, SDH, Succinate Dehydrogenase Complex Subunit B, Iron Sulfur (Ip), Succinate Dehydrogenase [Ubiquinone] Iron-Sulfur Subunit, SDHIP, CWS2, PGL4, SDH2
    4d
    Succinate Dehydrogenase-Deficient Cancer Cells Have Increased Susceptibility to Ym155-Induced DNA Damage. (PubMed, Endocr Relat Cancer)
    In summary, accumulation of succinate in SDH-deficient tumors inhibited KDM4 activity, impaired DNA repair and yielded enhanced susceptibility to Ym155-induced reactive oxygen species (ROS) generation. The identified intrinsic susceptibilities of SDHB-deficient cancers have the potential to be therapeutically leveraged.
    Journal
    |
    SDHB (Succinate Dehydrogenase Complex Iron Sulfur Subunit B)
    |
    SDHB deficient
    7d
    Functional characterization of SDHB variants: Advancing succinate dehydrogenase biology and variant curation in hereditary paraganglioma. (PubMed, J Clin Invest)
    In this issue of the JCI, Lee et al. have described a newly developed cellular complementation assay for SDHB function that may assist variant curation in clinical practice and thereby improve outcomes for patients inheriting these cancer-risk variants.
    Journal
    |
    SDHB (Succinate Dehydrogenase Complex Iron Sulfur Subunit B)
    15d
    S100 Expression and SDHB Status Define Distinct Biological Subsets of Bladder Paraganglioma. (PubMed, Hum Pathol)
    These findings demonstrate that diffuse S100 positivity in bladder paraganglioma is relatively common and represents a significant diagnostic pitfall. Importantly, S100-positive tumors appear to be associated with intact SDHB expression and a potentially less aggressive phenotype, whereas SDHB loss identifies a higher-risk subset with increased metastatic potential.
    Journal
    |
    SDHB (Succinate Dehydrogenase Complex Iron Sulfur Subunit B) • SOX10 (SRY-Box 10)
    17d
    LEAH: Cohort Evaluation of Body Fluids Early Detection of Cancer in High-risk Individuals (clinicaltrials.gov)
    P=N/A, N=5909, Not yet recruiting, Gustave Roussy, Cancer Campus, Grand Paris | Initiation date: Jun 2025 --> Feb 2026
    Trial initiation date
    |
    TP53 (Tumor protein P53) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • PTEN (Phosphatase and tensin homolog) • STK11 (Serine/threonine kinase 11) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • POLE (DNA Polymerase Epsilon) • RUNX1 (RUNX Family Transcription Factor 1) • BAP1 (BRCA1 Associated Protein 1) • ETV6 (ETS Variant Transcription Factor 6) • MLH1 (MutL homolog 1) • CDK4 (Cyclin-dependent kinase 4) • MSH2 (MutS Homolog 2) • SMAD4 (SMAD family member 4) • CDH1 (Cadherin 1) • SDHB (Succinate Dehydrogenase Complex Iron Sulfur Subunit B) • POLD1 (DNA Polymerase Delta 1) • RAD51C (RAD51 paralog C) • CEBPA (CCAAT Enhancer Binding Protein Alpha) • RAD51D (RAD51 paralog D) • DDX41 (DEAD-Box Helicase 41) • GATA2 (GATA Binding Protein 2) • DICER1 (Dicer 1 Ribonuclease III) • FLCN (Folliculin) • PRSS1 (Serine Protease 1) • SDHD (Succinate Dehydrogenase Complex Subunit D) • TXNIP (Thioredoxin Interacting Protein) • ANKRD26 (Ankyrin Repeat Domain Containing 26) • BMPR1A (Bone Morphogenetic Protein Receptor Type 1A) • HOXB13 (Homeobox B13)
    |
    TP53 mutation • PTEN deletion
    18d
    Clinicopathological and molecular features of acquired cystic disease-associated renal cell carcinoma (PubMed, Zhonghua Bing Li Xue Za Zhi)
    ACD-RCC is a rare renal cell carcinoma that occurs in patients with end-stage renal disease and has unique morphological features. It is often associated with favorable prognosis and alterations in genes related to the MTOR/TSC pathway or chromatin modification.
    Journal
    |
    ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • KMT2C (Lysine Methyltransferase 2C) • TSC2 (TSC complex subunit 2) • SMARCB1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily B, Member 1) • SDHB (Succinate Dehydrogenase Complex Iron Sulfur Subunit B) • TSC1 (TSC complex subunit 1) • SETD2 (SET Domain Containing 2, Histone Lysine Methyltransferase) • TFE3 (Transcription Factor Binding To IGHM Enhancer 3) • MME (Membrane Metalloendopeptidase) • KMT2B (Lysine Methyltransferase 2B) • GATA3 (GATA binding protein 3) • PAX8 (Paired box 8) • TFEB (Transcription Factor EB 2)
    |
    TP53 mutation
    19d
    Bladder Paraganglioma With Rapid Metastasis: A Case Report and Review of the Literature. (PubMed, Cureus)
    A unique challenge in this case was related to social determinants of health, which, in this patient, were associated with difficulty maintaining appointments. In treating a patient with hematuria, it is important to consider paraganglioma (PGL) as a differential diagnosis to optimize treatment.
    Journal
    |
    SDHB (Succinate Dehydrogenase Complex Iron Sulfur Subunit B)
    19d
    Diagnostic practice and awareness of SDH- and FH-deficient renal cell carcinoma: results from an Italian Study Group of uropathology (GIUP) survey. (PubMed, Virchows Arch)
    Overall, metabolic RCC recognition in Italy is primarily morphology-driven but constrained by uneven access to confirmatory IHC, particularly 2SC, and to molecular assays. The findings argue for harmonized diagnostic algorithms, regional reference laboratory networks, and routine involvement of molecular tumor boards, supported by targeted educational initiatives (including curated digital slide repositories), to standardize practice and improve patient pathways from morphologic suspicion to genetic counselling and tailored surveillance.
    Journal
    |
    SDHB (Succinate Dehydrogenase Complex Iron Sulfur Subunit B) • FH (Fumarate Hydratase)
    24d
    Elucidation of gene clusters underlying withanolide biosynthesis in ashwagandha through yeast metabolic engineering. (PubMed, Nat Plants)
    Identifying SULF1 as a core pathway enzyme challenges the conventional paradigm of sulfotransferases as tailoring enzymes and suggests a wider role for this enzyme family in plant specialized metabolism. This work opens new avenues for the sustainable production of withanolides through biomanufacturing and for drug development leveraging the withanolide scaffold.
    Journal
    |
    SDHB (Succinate Dehydrogenase Complex Iron Sulfur Subunit B)
    26d
    Clinical and Genetic Characteristics of Pheochromocytoma and Paraganglioma: A Single-Center Experience Including a Rare VHL Variant. (PubMed, J Clin Med)
    The identification of a rare VHL c.369delG variant, previously unreported in association with PPGL, within a characteristic VHL-related clinical phenotype highlights the importance of this association. Similarly, atypical NF1 cases emphasize phenotypic variability and reinforce the importance of germline testing even in clinically silent presentations.
    Journal
    |
    NF1 (Neurofibromin 1) • SDHB (Succinate Dehydrogenase Complex Iron Sulfur Subunit B) • SDHA (Succinate Dehydrogenase Complex Flavoprotein Subunit A)
    1m
    Succinate dehydrogenase B palmitoylation promotes T cell exhaustion through the H3K27ac-PD1 axis in pancreatic cancer. (PubMed, Cancer Lett)
    As a competitive inhibitor, CPP-S1 inhibits the palmitoylation modification of SDHB, reduces the SDHB protein level, and suppresses the tumor growth of pancreatic cancer cells, with enhanced effects when used in combination with anti-PD1 therapy. These findings reveal a new strategy to overcome the immune escape mediated by the DHHC5-SDHB axis in pancreatic cancer immunotherapy.
    Journal
    |
    SDHB (Succinate Dehydrogenase Complex Iron Sulfur Subunit B)
    1m
    Hemangioblastoma of the Kidney-A Comprehensive Clinical, Pathological, and Genetic Analysis of Four Cases. (PubMed, APMIS)
    Its favorable prognosis underscores the importance of distinguishing it from ccRCC to prevent unnecessary treatments. Further research is warranted to elucidate the underlying genetic mechanisms.
    Journal
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • VHL (von Hippel-Lindau tumor suppressor) • SDHB (Succinate Dehydrogenase Complex Iron Sulfur Subunit B) • NCAM1 (Neural cell adhesion molecule 1) • CA9 (Carbonic anhydrase 9) • MME (Membrane Metalloendopeptidase) • PAX8 (Paired box 8)
    |
    VHL mutation
    1m
    Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation and SDHB Deficient GIST) in the Post-imatinib Second-line Setting. (clinicaltrials.gov)
    P2, N=3, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting | N=30 --> 3
    Enrollment closed • Enrollment change
    |
    SDHB (Succinate Dehydrogenase Complex Iron Sulfur Subunit B)
    |
    imatinib • Stivarga (regorafenib)